Success Story: NIW Approved Without RFE! We Helped a Postdoctoral Fellow Secure Success
Client’s Testimonial:
"Thank you very much for your support throughout my NIW process. I truly appreciate your professionalism and guidance.”
On May 26th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the Field of Cancer Research (Approval Notice).
General Field: Cancer Research
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: China
Approval Notice Date: May 26th, 2026
Processing Time: 5 months, 22 days (Premium Processing Upgrade Requested)
Case Summary:
Developing more effective cancer therapies requires more than identifying tumors after they appear. It demands a deeper grasp of the biological mechanisms that drive cancer initiation, progression, immune evasion, tumor metabolism, and drug resistance. The client's research operates precisely in this space, uncovering mechanisms underlying cancer development and using that knowledge to advance small-molecule therapeutics that target tumor metabolism and immune regulation.
Rather than presenting publications as standalone achievements, the case was organized around the client's core research contributions in cancer biology, tumor immunology, tumor metabolism, and drug discovery. Together, these lines of work showed how the client has helped advance understanding of immune suppression, tumor microenvironment regulation, cancer recurrence, and therapeutic strategies designed to improve anti-tumor efficacy.
North America Immigration Law Group (NAILG) organized the evidence so USCIS could evaluate the impact through clear, objective indicators:
- Peer-review activity: 14 completed reviews for journals in cancer biology, pharmacology, biomedical research, and related fields.
- Publication record: 13 peer-reviewed journal articles, including 6 first- or co-first-authored articles, 1 first-authored preprint, 2 books, and 2 first-authored granted patents.
- Citation reliance: 165 citations to the client's published body of work, including multiple papers ranked among highly cited clinical medicine publications for their respective years.
USCIS approved the I-140 National Interest Waiver petition, recognizing a record defined by meaningful scholarly influence, trusted peer-review service, patent activity, and a proposed endeavor aligned with urgent U.S. needs in cancer therapy development. We congratulate the client on this milestone and look forward to the continued impact of her work in advancing effective cancer treatments, overcoming drug resistance, and supporting United States leadership in cancer research.

